Hepatitis C Virus-Related Lymphomagenesis in a Mouse Model by Tsukiyama-Kohara, Kyoko et al.
International Scholarly Research Network
ISRN Hematology
Volume 2011, Article ID 167501, 8 pages
doi:10.5402/2011/167501
Review Article
Hepatitis C Virus-RelatedLymphomagenesisin a Mouse Model
Kyoko Tsukiyama-Kohara,1 Satoshi Sekiguchi,2 YuriKasama,1
Nagla Elwy Salem,1,3,4 Keigo Machida,5 and Michinori Kohara2
1Department of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto-shi,
Kumamoto 860-8556, Japan
2DepartmentofMicrobiologyandCellBiology,TheTokyoMetropolitanInstituteofMedicalScience,2-1-6Kamikitazawa,Setagaya-ku,
Tokyo 156-8506, Japan
3Department of Medical Virology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto-shi,
Kumamoto 860-8556, Japan
4Clinical Pathology Department, Faculty of Medicine, Suez Canal University, Round Road Kilo 4.5, Ismailia, Egypt
5Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles,
CA 90033, USA
Correspondence should be addressed to Kyoko Tsukiyama-Kohara, kkohara@kumamoto-u.ac.jp
Received 5 May 2011; Accepted 2 June 2011
Academic Editors: D. Efremov and L. Visser
Copyright © 2011 Kyoko Tsukiyama-Kohara et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Bcellnon-HodgkinlymphomaisatypicalextrahepaticmanifestationfrequentlyassociatedwithhepatitisCvirus(HCV)infection.
The mechanism by which HCV infection leads to lymphoproliferative disorder remains unclear. Our group established HCV
transgenic mice that expressed the full HCV genome in B cells (RzCD19Cre mice). We observed a 25.0% incidence of diﬀuse large
B cell non-Hodgkin lymphomas (22.2% in male and 29.6% in female mice) within 600 days of birth. Interestingly, RzCD19Cre
mice with substantially elevated serum-soluble interleukin-2 receptor α-subunit (sIL-2Rα)l e v e l s( >1000pg/mL) developed B cell
lymphomas. Another mouse model of lymphoproliferative disorder was established by persistent expression of HCV structural
proteins through disruption of interferon regulatory factor-1 (irf-1 / /CN2 mice). Irf-1 / /CN2 mice showed extremely high
incidences of lymphomas and lymphoproliferative disorders. Moreover, these mice showed increased levels of interleukin (IL)-2,
IL-10, and Bcl-2 as well as increased Bcl-2 expression, which promoted oncogenic transformation of lymphocytes.
1.Introduction
The incidence of non-Hodgkin lymphoma (NHL) is rising
worldwide and is higher in developed countries than in
Africa and Asia [1]. B cell non-Hodgkin lymphoma is a
typical extrahepatic manifestation frequently associated with
hepatitis C virus (HCV) infection [2]. The prevalence of
HCV infection in patients with B cell non-Hodgkin lym-
phomaisapproximately15%[3].TheHCVenvelopeprotein
E2 binds human CD81 [4], a tetraspanin expressed on
various types of cells, including lymphocytes, and activates
B cell proliferation [5]. Infection and replication of HCV
were observed in B cells [6, 7] although the direct eﬀects,
particularly in vivo, have not been clariﬁed. To determine the
direct eﬀect of HCV infection on B cells in vivo, we crossed
transgenic mice with an integrated full-length HCV genome
(Rz) under the conditional Cre/loxP expression system, with
mice expressing the Cre enzyme [8] under transcriptional
control of the B lineage-restricted gene CD19 [9].
To investigate the mechanism of development of lym-
phoproliferation or B cell non-Hodgkin lymphoma in HCV
patients, we also developed a transgenic mouse model that
conditionallyexpressedHCVcDNA(nucleotides294–3435),
including the viral genes that encode the core, E1, E2, and
NS2 proteins, by using the Cre/loxPs y s t e m( i nc o r e - N S 2
[CN2] mice) [10, 11]. Conditional transgene activation of
the HCV cDNA (core, E1, E2, and NS2) protects mice
from Fas-mediated lethal acute liver failure, by inhibiting
cytochrome c release from mitochondria [11]. Persistent
HCV protein expression is established by targeted disruption2 ISRN Hematology
of interferon regulatory factor-1 (irf-1), and high incidences
of lymphoproliferative disorders are noted in irf-1−/− CN2
mice [12].
Previously, transgenic mice that expressed the HCV core
protein were established using a promoter derived from
hepatitis B virus [13], whereas mice that expressed structural
or complete viral proteins were established using promoters
derived from the albumin gene [14] .T h e s em i c ew e r ei m -
munotolerant to the transgene and did not develop hepatic
inﬂammation. However, they developed age-related hepatic
steatosisandhepatocellularcarcinomas.Incontrast,theCN2
mice used in the present study were not immunotolerant
to the HCV gene and developed hepatitis after the onset
of HCV gene expression. However, the expression of HCV
in these mice was usually lost after 21 days. Therefore,
an animal model of persistent HCV protein expression is
required for examining the eﬀects of chronic HCV infection
in vivo.
IFN signaling mediates tumor-suppressor eﬀects and
antiviral responses and is regulated by key transcription fac-
tors of the interferon-regulatory factor (IRF) protein family,
including IRF1, IRF2, IRF3, IRF7, and IRF9. Targeted dis-
ruption of irf-1 results in aberrant lymphocyte development
anda marked reductionin the number of CD8+ Tcellsinthe
peripheral blood, spleen, and lymph nodes [15]. In addition,
natural killer cell development is impaired in irf-1−/− mice
[16]. The mechanisms by which HCV infection induces IFN
resistance and inﬂuences the development of lymphomas
are poorly understood. Therefore, we established an irf-1−/−
CN2 mouse model of persistent HCV expression, which
allowed us to investigate the eﬀects of HCV on lymphatic
tissue tumor development.
2.SpontaneousDevelopment of BCell
Lymphomas in the RzCD19CreMouse
The full-genome HCV expression was induced by the Cre/
loxP system with CD19Cre (Figure 1(A)). Expression of
HCV was mainly induced in B cells (Figure 1(B)). The
incidence of B cell lymphomas in RzCD19Cre mice was
25.0% (22.2% in male and 29.6% in female mice) and was
signiﬁcantly higher than the incidence in the HCV-negative
groups. Lymphomas were diagnosed as typical diﬀuse
B cell non-Hodgkin lymphomas. Most were CD45R positive
and located in the mesenteric lymph nodes (Figure 1(C)).
Some were identiﬁed as intrahepatic lymphomas (incidence,
4.2%). HCV e x p r e s s i o nw a sd e t e c t e di na l lBc e l ll ym p h o m a s
of RzCD19Cre mice. Indeed, the expression of the HCV or
HCVproteinsinducesthespontaneousdevelopmentofBcell
lymphomas, irrespective of the integrated site in the mouse
genome.
Serum concentrations of IL-1α,I L - 1 β, IL-2, IL-3, IL-4,
IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17,
eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α,M I P -
1β, RANTES, TNF-α,I L - 1 5 ,F G F - b a s i c ,L I F ,M - C S F ,M I G ,
MIP-2, PDGFβ, VEGF, alanine aminotransferase (ALT),
and aspartate aminotransferase (AST) were not signiﬁcantly
diﬀerent in the presence or absence of B cell lymphomas.
Interestingly, the average sIL-2Rα level was signiﬁcantly
higher in the sera from RzCD19Cre mice with B cell lym-
phomas(830.3 ± 533.0pg/mL)thaninthatfromtumor-free
controlgroups,includingtheRzCD19Cre,Rz,CD19Cre,and
wild-type (WT) mice (499.9 ± 110.2pg/mL;P<0.0057)
(Figure 1(D)). The diﬀerence in the average sIL-2Rα levels
between the sera from groups with tumors other than B cell
lymphomas (430.46 ± 141.1 5p g / m L )a n dt h a tf r o mt u m o r -
free control groups was insigniﬁcant (P>0.05). Moreover,
all RzCD19Cre mice with a relatively high level of sIL-2Rα
(>1000pg/mL) presented with B cell lymphomas. A signiﬁ-
cantincreaseinsIL-2RαwasalsoobservedinMxCre/CN2-29
mice that expressed the HCV CN2 gene [8]a n dh a dBc e l l
lymphomas, compared with tumor-free control (CN2-29)
mice.
To examine whether sIL-2Rα was derived from lym-
phoma tissues, we quantiﬁed IL-2Rα concentrations in
splenocytes, peripheral blood lymphocytes (PBLs), and B
cell lymphoma tissues. The concentration of IL-2Rα was
signiﬁcantly higher in splenocytes from RzCD19Cre mice
than in splenocytes from CD19Cre mice. Moreover, the
concentration of IL-2Rα in B cell lymphoma tissues from
RzCD19Cre mice was higher than that in splenocytes [8].
These results strongly suggest that B cell lymphomas directly
contribute to the elevated serum concentrations of sIL-
2Rα in RzCD19Cre mice. They also strongly support the
possibility that persistent expression of HCV could directly
induce transformation of B cells.
3. PersistentHCVExpressionand
Lymphoproliferative Disorder
RzCD19Cre mice are immunotolerant to HCV, because
HCV is expressed in B cells before birth. In contrast,
CN2 mice express HCV after they are administered the
recombinant adenovirus that expresses the Cre enzyme
(Figures2(a)and2(b)).TheexpressionofHCVinthesemice
is usually lost after 21 days (Figure 2(b)) through removal
of HCV-expressing hepatocytes by the immune response.
To establish persistent HCV expression, we disrupted irf-1
by crossing of RzCD19Cre mice with irf-1−/− mice. IRF-1
plays a signiﬁcant role in the Th1-type immune response
and its absence is expected to decrease the elimination
of HCV-expressing cells. As expected, HCV expression
in irf-1−/− CN2 mice persisted for more than 500 days
(Figure 2(c)).
A signiﬁcant percentage of the mice that expressed the
HCV core protein (irf-1−/− CN2 mice) showed polyclonal
lymphoid growth disturbances, including splenomegaly,
expanded lymph nodes, adenocarcinoma in the abdomen or
leg, and lymphoma of the liver or Peyer’s patches (Figures
2(d) and 2(e)). In contrast, hepatocytes with abundant
expression of HCV proteins rarely developed into hepato-
cellular carcinomas. Hematoxylin and eosin (H&E) staining
of splenomegalic tissue showed extensive hyperplasia of the
white pulp zones, in which the cortical zones contained
lymphoid follicles and scattered germinal centers although
mitotic ﬁgures were rarely observed. These results indi-
cate that persistent expression of HCV proteins frequently
induces lymphoproliferative disorders in addition to liverISRN Hematology 3
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Figure 1: (A) The structure of the hepatitis C virus (HCV) transgene (HCR6-Rz); HCV gene expression was regulated by the Cre/loxP
expression cassette (upper). The Cre transgene was located in the CD19 locus (bottom). (B) Expression of HCV core protein in the liver,
spleen, and plasma of RzCD19Cre mice was quantiﬁed by core ELISA. Data represent the mean (SD) (n = 3). (C) Histological analysis
of tissues from a normal mouse (a, c, e; lymph node from CD19Cre mouse; b, d, f) and B cell lymphoma (b, d, f; RzCD19Cre mouse).
Paraformaldehyde-ﬁxed and paraﬃn-embedded tumor tissues were stained with hematoxylin and eosin (H&E) (c–f); immunostaining of
lymphoma with anti-CD45R (g) and anti-CD3 (h) is indicated. Scale bars, 100μm (c, d) and 20μm (g, h); arrow heads indicate mitotic cells.
(D) Concentration of sIL-2Rα in serum samples from tumor-free control mice, and RzCD19Cre and wild-type (WT) mice with or without
B-cell lymphomas or other tumors.4 ISRN Hematology
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Figure 2: (a) The structure of the HCV transgene (core-NS2); gene expression was regulated by the Cre/loxP expression cassette. (b) and
(c) Serum alanine aminotransferase (ALT) levels and core protein expression ELISA system in hepatocytes from CN2-8 (b) and irf-1−/−
CN2-8 (c) mice after administration of AxCANCre (n = 225 for irf-1−/−, n = 75 for irf-1−/− CN2-29, n = 150 for irf-1−/− CN2-8,
n = 225 for wild type, n = 75 for CN2-29, and n = 150 for CN2-8; total n = 900). (d) HCV protein expression enhanced hyperplasia
in male and female CN2 and irf-1−/− CN2 mice. The occurrence of hyperplasia was monitored every 7 days for 600 days after administration
of AxCANCre. (e) Histological analysis of spontaneous proliferative disturbances in CN2 transgenic mice. Of the 900 mice injected with
AxCANCre, 25 of 75 (33%) CN2-29, 47 of 150 (31%) CN2-8, 29 of 75 (39%) irf-1−/− CN2-29, and 62 of 150 (41%) irf-1−/− CN2-8 mice
developed proliferative disturbances.ISRN Hematology 5
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Figure 3: (a) Serum IL-2, IL-4, IL-10, and IL-12 levels in irf-1+/+ CN2 (Tg+) and irf-1+/+ WT mice measured by ELISA. P values <0.05
were considered signiﬁcant. (b) Serum IL-2, IL-4, IL-10, and IL-12 levels in irf-1−/− CN2 (Tg+) and irf-1−/− WT mice measured by ELISA.
P values are based on the mean cytokine concentrations. (c) Bcl-2 protein levels in the lymph nodes of irf-1+/+ WT and irf-1−/− WT or
transgenic (CN2-29) mice on day 0, day 400, and day 500 after administration of AxCANCre. Bcl-2 migrated at 26kD.
hyperplasia, which is consistent with the phenotype of
patients with hepatocellular carcinoma.
The average ratio of T cells to B cells in the lymph nodes
and spleens of CN2 mice was signiﬁcantly higher than that
in WT mice. The majority of CD3+ lymphocytes and a few
CD8+ lymphocytes expressed CD4 on their surfaces. The
proliferating cells were mainly CD4+ T cells although some
were CD45R+B cells. The irf-1−/− CN2 mice also developed
B cell lymphomas (data not shown). These results conﬁrm
that HCV protein expression induces lymphoproliferative
disorders that involve excessive expansion of both T cells
and B cells. The cell population that showed negative results
for T cell receptor (α, β, γ,a n dδ isoforms) staining
was smaller in irf-1−/− CN2 mice than that in the other
mice.
The disruption of irf-1 inhibited Fas-induced apoptosis,
presumablybydecreasingthelevelsofcaspase-6andcaspase-
7 messenger RNA. These results suggest that the reduced
expressionofeﬀectorcaspasesdelaysFas-mediatedapoptosis
in irf-1−/− mice and prevents the elimination of HCV-ex-
pressing cells in vivo.
The CN2 mice showed signiﬁcantly increased levels of
serum IL-2, IL-10, and IL-12 (Figure 3(a)). Notably, the CN2
mice with proliferative disturbances in the lymph nodes and
spleen had dramatically elevated levels of these cytokines,
suggesting that altered cytokine production is involved in
aberrant lymphocyte proliferation or diﬀerentiation. In con-
trast, the irf-1−/− CN2 mice did not show elevated levels of
serum IL-12, but had signiﬁcantly higher levels of serum IL-
2 and IL-10 than did irf-1−/− mice (Figure 3(b)). Thus, the
disruption of irf-1 negated the increase in the IL-12 level, but
augmented the increases in the levels of IL-2 and IL-10 in
CN2 mice. These resultsindicate that IL-2 and IL-10 play key
roles in the induction of the lymphoproliferative phenotype
in irf-1−/− CN2 mice. A signiﬁcantly positive correlation was
found between the cytokine levels and spleen weights of CN2
gene-expressing mice with the irf-1+/+ background (R =
0.43, P<0.05, and R = 0.53, P<0.05, resp.). These
results indicate that IL-2 and IL-10 are involved in lym-
phoproliferation in viral protein-expressing mice.
Bcl-2 is an integral inner mitochondrial membrane
protein, overexpression of which blocks the apoptotic death6 ISRN Hematology
Table 1: Synergistic eﬀects of cytokines on Fas-induced apoptosis in irf-1−/− CN2 mice.
None IL-2 + IL-10 IL-2 + IL-12 IL-10 + IL-12
WT mice
Bcl-2 fold increase −−−−
Annexin V + percentage ∗∗∗∗ ∗∗∗∗ ∗∗∗∗ ∗∗∗∗
Caspase-9 ∗∗ ∗∗ ∗∗ ∗∗
Caspase-3/7 ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗
irf-1−/− mice
Bcl-2 fold increase −−−−
Annexin V + percentage ∗∗∗ ∗∗∗ ∗∗∗ ∗∗∗
Caspase-9 ∗∗ ∗∗ ∗∗ ∗∗
Caspase-3/7 ∗∗ ∗∗ ∗∗ ∗∗
CN2-29 mice
Bcl-2 fold increase − + −−
Annexin V + percentage ∗∗∗ ∗∗ ∗∗∗ ∗∗∗
Caspase-9 ∗∗ ∗ ∗ ∗∗
Caspase-3/7 ∗∗ ∗ ∗ ∗
irf-1−/− CN2-29 mice
Bcl-2 fold increase + +++ ++ ++
Annexin V + percentage ∗∗ − ∗∗
Caspase-9 ∗∗ − ∗∗
Caspase-3/7 ∗ − ∗∗
Bcl-2: −, less than 2-fold increase; +, more than 2-fold increase; ++, more than 4-fold increase; +++, more than 6-fold increase (in comparison with mock
treatment).
AnnexinV: −,lessthan20%decrease; ∗,upto20%decrease; ∗∗,upto40%decrease; ∗∗∗,upto60%decrease; ∗∗∗∗,morethan60%decrease(incomparison
with mock treatment).
Caspase-9: −, less than 10-fold decrease; ∗, up to 50-fold decrease; ∗∗, up to 200-fold decrease; ∗∗∗, up to 400-fold decrease; ∗∗∗∗, more than 400-fold
decrease (in comparison with mock treatment).
Caspase-3/7: −, less than 200-fold decrease; ∗, up to 500-fold decrease; ∗∗, up to 1000-fold decrease; ∗∗∗, more than 1000-fold decrease (in comparison with
mock treatment).
of pro-B-lymphocyte death [17]. Bcl-2 transgene expression
increases the oncogenic potential [18] and is linked with B
cell neoplasm and t(14;18) translocation [19]. We therefore
examined the level of Bcl-2 protein and found that it was
upregulated in the lymph nodes of irf-1−/− CN2 mice after
400 days (Figure 3(c)).
IL-10 treatment in the presence of IL-2 greatly inhibited
Fas-induced apoptosis in irf-1−/− CN2 mice compared with
other groups (Table 1). Furthermore, irf-1 disruption accel-
erated the resistance of splenocytes to Fas-induced apoptosis
in the presence of IL-2, IL-10, and/or IL-12. In particular,
IL-2 plus IL-10 treatment produced the strongest upregu-
lation of the Bcl-2 mRNA levels in splenocytes of irf-1−/−
CN2 mice. This indicates that IL-2, IL-10, and/or IL-12
contribute to upregulation of bcl-2 expression, which sub-
sequently inhibits Fas-induced apoptosis. Caspase-9 and
caspase-3/7 activities were inversely correlated with the
level of bcl-2 expression. These results indicate that aber-
rant cytokine expression and disruption of IFN signal-
ing aﬀect bcl-2 expression synergizing with HCV pro-
teins, which is associated with the inhibition of caspase
expression.
Table 2: Synergistic eﬀects of cytokines on Bcl-2 expression in WT
and irf-1−/− mice in the presence of HCV core protein.
WT mice irf-1−/− mice
Mock −−
IL-2 + IL-10 + +++
IL-2 + IL-12 + ++
IL-10 + IL-12 + ++
IL-2 −−
IL-10 + ++
IL-12 −−
I L - 2+I l - 1 0+I L - 1 2 − +
Bcl-2: −, less than 2-fold increase; +, more than 2-fold increase; ++, more
than 4-fold increase; +++, more than 5-fold increase (in comparison with
mock treatment).
HCV core protein induced IL-2 and IL-10. Envelope
protein E2 induced IL-12 expression. These results indicate
that the HCV core and E2 proteins are responsible for IL-2,
IL-10, and IL-12 expression. Core protein expression and
IL-10 stimulation most strongly induced Bcl-2 expressionISRN Hematology 7
(Table 2). From these results, core protein contributes signif-
icantly to the induction of Bcl-2 in the presence of cytokines.
4. Conclusion
Our results show that the conditional expression of HCV
proteins induces inﬂammation and lymphoproliferative dis-
orders. Furthermore, established animal models will prob-
ably provide critical information for the elucidation of
the molecular mechanism(s) underlying the spontaneous
development of B cell non-Hodgkin lymphoma after HCV
infection. The disruption of irf-1 enhances lymphoprolifer-
ative disorders. Therefore, IRF-1-inducible genes probably
play essential roles in suppressing HCV-induced lymphoma
and in eliminating HCV protein-expressing cells. The over-
expression of apoptosis-related proteins (including Bcl-2)
and/or aberrant cytokine production are the primary events
in HCV-induced lymphoproliferation.
The HCV gene has the potential to induce B cell lym-
phomasinRzCD19Cremice,withoutinducinghostimmune
responses against HCV gene product. This is in agreement
with the results of a previous study, which indicate that viral
elimination reduces the incidence of malignant lymphoma
in patients infected with HCV [20]. The incidence of B cell
lymphoma in the HCV transgenic mouse strain (MxCre/
CN2-29) is high, and this strongly suggests that development
of B cell lymphomas occurs via expression of the HCV
transgene.
Recent ﬁndings indicate a link between sIL-2Rα levels
and hepatocellular carcinoma in Egyptian patients [21]. The
level of IL-2Rα was higher in splenocytes of RzCD19Cre
mice than in those of CD19Cre mice; however, the dif-
ferences in the serum concentrations of sIL-2Rα between
RzCD19Cre mice without B cell lymphomas and other con-
trol groups (Rz, CD19Cre, and WT) were insigniﬁcant.
These results indicate that HCV increases IL-2Rα expression
in B cells; proteolytic cleavage of IL-2Rα increased after
B cell lymphoma development in the RzCD19Cre mice.
The detailed mechanism by which HCV expression induces
IL-2Rαremainsunclear,butHCVcoreproteininducesIL-10
expression in mouse splenocytes [12]. IL-10 upregulates the
expression of IL-2Rα (Tac/CD25) in normal and leukemic B
lymphocytes [22]. Therefore, through IL-10, the HCV core
protein might induce IL-2Rα in B cells of the RzCD19Cre
mouse.
Disruption of irf-1 enables the persistent expression of
HCV protein. This leads to lymphoproliferative diseases re-
sultingfromreducedapoptosis(i.e.,lowerlevelsofcaspase-1,
caspase-6, and caspase-7 expression). HCV CN2 transgenic
(Tg+) mice are resistant to Fas-induced apoptosis because
of the inhibition of cytochrome c release from mitochondria
[11]. Mice with disruption of irf-1 have several defects in
their innate and adaptive immunities, including lineage-
speciﬁc defects in thymocyte development, and the devel-
opment of immature T cells into mature CD4+ cells but
not CD8+ T cells [16, 23]. IRF-1 controls the positive and
negative selection of CD8+ thymocytes [24] and is required
for the development of the Th1-type immune response.
The absence of IRF-1 induces Th2-type immune response
[16, 25]. The number of natural killer cells is dramatically
reduced in irf-1−/− mice [16]. This defect may markedly
increase viral protein expression and inhibit tumor surveil-
lance mechanisms, leading to the development of non-
Hodgkin lymphoma. Expression of the IL-12 p40 subunit is
defective in irf-1−/− mice [16].
Hypermutation of the immunoglobulin genes in B cells
induced by HCV infection is the cause of the lymphoma-
genesis observed in HCV infection [16, 26]. This ﬁnding
may provide a more direct insight into lymphoma produc-
tion, because HCV-induced hypermutation causes genetic
instability and chromosomal aberrations, possibly resulting
in neoplastic transformation [27]. In addition, the anti-
apoptotic phenotype resulting from sustained viral protein
expression may enhance the survival of lymphocytes and
inhibit activation-induced cell death to turn oﬀ the activated
lymphocytes. The dysregulated cytokine proﬁles and sus-
tained lymphocyte survival may alter the fates of regulatory
T cells and dendritic cells [28].
In summary, the mouse model of B cell lymphoma and
lymphoproliferative disorder represents a powerful tool to
address the molecular mechanism of lymphoma develop-
ment by HCV.
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